trending Market Intelligence /marketintelligence/en/news-insights/trending/faknujcPG_BHm1_heMwSUA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Alphaeon splits into 2 business units, changes name to AEON Biopharma

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Alphaeon splits into 2 business units, changes name to AEON Biopharma

Alphaeon Corp. will be split up into two business units as part of a restructuring aimed at simplifying its corporate structure.

The Irvine, Calif.-based company has been renamed to AEON Biopharma Inc. and will focus on developing its botulinum toxin complex ABP-450, or prabotulinumtoxinA, for treating debilitating medical conditions.

The second unit is named Alphaeon1 LLC and will provide the company's stockholders a way to continue to hold about 8.7 million shares of Evolus Inc. that were previously held by Alphaeon.

Alphaeon said the units will retain the same shareholder base that was in place prior to the split.